Edgar Filing: SCOLR Pharma, Inc. - Form 4/A

SCOLR Ph	arma, Inc.									
Form 4/A										
May 20, 20	05									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB APPROVAL	
	Washington, D.C. 20549								3235-0287	
	Check this box							Expires:	January 31,	
if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF								Estimated	2005	
Section 16. SECURITIES								burden hou	-	
	Form 4 or							response	•	
Form 5							ange Act of 1934,			
obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section										
See Inst		30(h)	of the I	nvestmen	t Compa	ny Act of	1940			
1(b).										
(Drint or Type	(Desponses)									
(Print or Type	(Responses)									
1. Name and Address of Reporting Person [*] 2. Issuer Name and Ticker or Trading 5. Relationship of							f Reporting Per	rson(s) to		
VITULLI GAIL			2. Issuer Name and Ticker or Trading Symbol				Issuer			
			SCOLR Pharma, Inc. [DDD]							
		AC 11 1 \				(Cheo	(Check all applicable)			
(Last)	(First) ((Middle)		of Earliest 7	Transaction		Director	100	7 Owner	
(Month/Day/Year) Director C/O SCOLR PHARMA, INC., 3625 12/06/2004X_ Officer (giv.								% Owner her (specify		
						below)	below)			
1521(D 1	· · Li (01 5.1., 50	JIL 500					Dir of Fir	ance/Princ Fin	l Ofer	
	(Street)		4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
				onth/Day/Yea	ar)		Applicable Line)			
12/08/200				2004				rm filed by One Reporting Person m filed by More than One Reporting		
BELLEVU	JE, WA 98006						Person		1 0	
(City)	(State)	(Zip)	Tał	ble I - Non-	Derivative	Securities	Acquired, Disposed o	f, or Beneficia	lly Owned	
1.Title of	2. Transaction Date			3.	4. Securit			6. Ownership	7. Nature of	
Security	(Month/Day/Year)	Execution	Date, if		onAcquired			Form: Direct	Indirect	
(Instr. 3)		any (Month/Day/Year)		Code (Instr. 8)	Disposed (Instr. 3,		Beneficially (D Owned (I)	D) or Indirect	Beneficial Ownership	
(Monu)		(month/Da	uy/ I cui)	(1131.0)	(111511.5,	i und 5)		Instr. 4)	(Instr. 4)	
						(A)	Reported			
						or	Transaction(s)			
				Code V	Amount	(D) Pric	(Instr. 3 and 4)			
Reminder: Re	eport on a separate lin	e for each cl	ass of sec	curities bene	eficially ow	ned directly	y or indirectly.			
Persons who respond to the collection of SEC 1474										
							ntained in this form		(9-02)	
					requi	red to res	pond unless the for	m		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned


 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

displays a currently valid OMB control number.

8 E S

Edgar Filing: SCOLR Pharma, Inc. - Form 4/A



Gail Vitulli	05/19/2005		
** Signature of	Date		

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option is exercisable as to one-third (1/3rd) of the total shares on 12/6/05, with the remainder to vest in twenty-four (24) equal (1)monthly installments beginning 1/6/06.
- (2) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.